Luke T. Shannon

Practice focus. Luke T. Shannon is a Chicago-based patent litigator whose practice centers on Hatch-Waxman/ANDA pharmaceutical litigation — Paragraph IV notice letters, non-infringement and invalidity opinions, design-around counseling, and post-grant proceedings. His technical work spans small molecules, compositions and formulations, polymorphs, methods of treatment, and pharmaceutical salt forms, with additional prosecution and freedom-to-operate experience in aerosol propellants, consumer products, and sustainable power generation (sources: IPWatchdog profile; National Law Review bio; Taft firm releases).

Side preference and firm context. His single tracked appearance is plaintiff-side (1–0), representing Candela Corporation against Nikolai Tankovich at Polsinelli. Consistent with his firm bios, he works for operating companies — brand pharmaceutical and life-sciences clients — typically as innovator-side counsel in ANDA disputes, though the related Delaware litigation in the tracked matter saw him defending Candela as counterclaim defendant. He joined Polsinelli's Chicago office as an Intellectual Property shareholder and Hatch-Waxman Litigation Practice Group member, and by late 2025 he was practicing in Taft Stettinius & Hollister's Chicago office (Taft press releases, Oct. 2025). A March 2026 directory listing again identifies him with Polsinelli, so his current affiliation is not fully settled from public sources.

Notable matters and PTAB/IPR experience. The tracked case is Candela Corporation v. Tankovich (IPR2023-00234), challenging U.S. Patent 10,675,481 covering a multi-wavelength fractional laser system for skin treatment. The PTAB instituted review but issued a Final Written Decision on June 5, 2024 finding no challenged claims unpatentable; Candela appealed to the Federal Circuit. The parallel Delaware action (Tankovich v. Candela Corp., 1:22-cv-01458) was stayed pending the IPR, where Shannon appeared pro hac vice for Candela. He advises clients on IPR/post-grant strategy and appeared as petitioner's counsel in this IPR, so PTAB experience is confirmed. He has also co-authored a chapter in the ABA's Biosimilars Litigation and Client Counseling and written on Hatch-Waxman topics for Law360.

Bar and education. Shannon holds a J.D. from IIT Chicago-Kent College of Law and a B.A. in chemistry, is registered with the USPTO, clerked for Judge Martin C. Ashman (N.D. Ill.), and previously worked as a chemist at a specialty biopharmaceutical company.